Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiac myosin inhibitors

Aficamten reduces cardiac contractility by modifying the actomyosin interaction

Nature Cardiovascular Research volume 3, pages 893–894 (2024)Cite this article

Subjects

Aficamten, a small-molecule myosin inhibitor, binds to the catalytic domain of cardiac myosin and reduces contraction by stabilizing the initial weak interaction between myosin and actin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Aficamten modes of action.

References

  1. Lehman, S. J., Crocini, C. & Leinwand, L. A. Nat. Rev. Cardiol. 19, 353–363 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Maron, M. S. et al. N. Engl. J. Med. 390, 1849–1861 (2024).

    Article  CAS  PubMed  Google Scholar 

  3. Hartman, J. H. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-024-00505-0 (2024).

    Article  Google Scholar 

  4. Scellini, B. et al. J. Gen. Physiol. 153, e202012789 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ma, W. et al. Circulation Res. 129, 617–630 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, University of Washington City, Seattle, WA, USA

    Farid Moussavi-Harami

  2. Department of Laboratory Medicine and Pathology, University of Washington, City, Seattle, WA, USA

    Farid Moussavi-Harami & Michael Regnier

  3. Center for Translational Muscle Research, University of Washington, City, Seattle, WA, USA

    Farid Moussavi-Harami & Michael Regnier

  4. Center for Cardiovascular Biology, University of Washington City, Seattle, WA, USA

    Farid Moussavi-Harami & Michael Regnier

  5. Institute for Stem Cell and Regenerative Medicine, University of Washington City, Seattle, WA, USA

    Farid Moussavi-Harami & Michael Regnier

  6. Department of Bioengineering, University of Washington City, Seattle, WA, USA

    Michael Regnier

Authors
  1. Farid Moussavi-Harami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Regnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Regnier.

Ethics declarations

Competing interests

M.R. is a founder, board member and equity holder in StemCardia, Inc. and a scientific advisory board member and equity holder in Kineabio, Inc. F.M-H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moussavi-Harami, F., Regnier, M. Aficamten reduces cardiac contractility by modifying the actomyosin interaction. Nat Cardiovasc Res 3, 893–894 (2024). https://doi.org/10.1038/s44161-024-00503-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-024-00503-2

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research